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ABSTRACT: The GABA, antagonist CGP 35348 was intraperito- 
neally given in doses of 100, 300, and 900 mglkg to old rats. 
These rats were earlier chronically provided with EEG and EMG 
electrodes. Sleep recordings based on visual inspection of EEG 
and EMG recordings were made for 3 h post injection, and spon- 
taneous behaviour in the recording cage was additionally ob- 
served. With 100 and 300 mglkg, the drug produced an increase 
in the duration of REM sleep compared to the saline-injected 
control group. The REM sleep latency was correspondingly re- 
duced. Non-REM sleep and total sleep duration increased and 
an s-shaped dose-response relationship was found. Explorative 
behaviour was diminished after injections with 100 and 300 mgl 
kg CGP 35348. The number and duration of spike-wave dis- 
charges were reduced after all doses of CGP 35348 and during 
all 3 recording hours. The latter outcomes confirm the strong 
suppressive action of this drug on spike-wave discharges; these 
effects have also been reported in models of absence epilepsy. 
The hypnotic properties and especially the increase in REM 
sleep after the administration of CGP 35348 deserve attention 
considering the paucity of drugs which facilitate REM sleep. The 
discovery of drugs promoting REM sleep might have theoretical 
as well as clinical consequences. 
KEY WORDS: GABAe antagonist, CGP 35348, Sleep, REM sleep, 
Old rats, Spike-wave discharges. 
INTRODUCTION 
GABA is a main inhibitory neurotransmitter in the mammalian 
brain. In several studies, different agents modulating GABA-ergic 
neurotransmission have been evaluated, and none of them found 
significant effects on sleep [20,21]. This is rather surprising, con- 
sidering the fact that GABA is an important inhibitory neurotrans- 
mitter and that benzodiazepines, the hypnotic drugs of choice, are 
assumed to exert heir action on the GABA-receptor complex. Men- 
delson and Martin [20] and Mendelson and Monti [21] studied the 
effects on sleep in rats of the benzodiazepine flurazepam, the 
GABAA agonist muscimol, and antagonist bicuculline. They found 
that only flurazepam facilitated sleep, but that both GABA-ergic 
compounds had only minimal effects. Apparently, that study does 
not support he hypothesis that the hypnotic actions of benzodiaze- 
pines are mediated by GABA-ergic mechanisms. 
However, GABA interacts with at least wo subtypes of GABA 
receptors, designated as GABAA and GABAB receptors, which show 
a heterogeneous di tribution in the brain. These two subtypes eem 
to be endowed with distinct neural functions [2,3,7]. Little is known 
about he role of GABAB in the regulation of sleep-wake states, 
and the role of GABAa agonists and antagonists on sleep-wake 
states hould be investigated. Recently, a centrally active GABAB 
antagonist, CGP 35348, has been described [2,7,9,23]. This drug is 
more potent han phaclofen, a weak GABAB antagonist, which is 
unable to pass the blood-brain barrier. It is already known that CGP 
35348 acts as a potent anti-absence drug in various rat and mouse 
models [11,16,17,18,28]. 
Also, considering the fact that various anti-epileptic drugs, 
such as barbiturates and benzodiazepines, have hypnotic effects, 
it was tentatively argued that CGP 35348 may alter sleep-wake 
states. In this context, the purpose of the present study was to 
examine the effects of the GABA8 antagonist CGP 35348 on 
sleep-wake states as well as on spike-wave discharges in the 
electroencephalogram (EEG). To establish the profile of this 
drug more extensively, the effects on behaviour were also stud- 
ied. Old rats showing spike-wave discharges in their EEG were 
used so that putative hypnotic and anti-epileptic effects of CGP 
35348 could be investigated atthe same time. 
METHODS 
Eight male Wistar ats, kindly donated by Troponwerke (Co- 
logne, Germany) with body weights between 389 and 460 g and 
ages of about 24 months, were used. Animals lived under a 12- 
12 LD cycle with white lights on at 2000 h. Red light was 
switched on during the dark period. Rats were implanted with a 
permanent tripolar EEG electrode set for recording the fronto- 
occipital EEG, and a bipolar electrode set for recording the nu- 
chal electromyogram (EMG) (for details, see [ 31 ] ). 
Rats were randomly assigned to one of four order groups of two 
subjects. All animals received saline, 100, 300, or 900 mg/kg CGP 
l Requests for reprints hould be addressed to Dr. E. L. J. M. van Luijtelaar, NICI, Department of Psychology, University of Nijmegen, PO Box 
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TABLE 1 
MEANS AND SEMS OF DURATION OF WAKEFULNESS /WAKE), NON-REM SLEEP, REM SLEEP, MEAN REM PERIOD 
LENGTH IN SECONDS, AND % REM SLEEP/TST ON THE FIRST, SECOND, AND THIRD HOUR 
AFTER INJECTION OF VARIOUS DOSES OF CGP 35348 
Doses CGP 35348 in mg/kg 
Hour 0 II)0 300 900 
1 
Wake 2691 ± 202 1950 + 119'+ 2062 _+ 138"+ 2730 + 144 
non-REM 805 + 162 1334 ~ 112"* 1289 + 123"¢ 842 + 128 
REM 84 ± 44 325 + 56~:", 237 + 51"+ 39 ± 19 
Mean REM 43.7 ± 10.9 49.0 :* 63 68.6 ± 19.1 50.3 +_ 24.4 
% REM/TST 6.5 ± 2.7 20.1 + 3.6*, 15.7 ± 3.2*¢ 3.1 ± 1.5 
Wake 2253 _± 269 2(104 ± 145 1545 _+ 180" 1362 + t92":~: 
non-REM 1084 + 234 131)8 ± 162i- 1516 + 71 1900 + 163" 
REM 226 _+ 55 324 ~ 61 556 + 71%+ 341 ± 82 
Mean REM 63.2 ~ 10.9 53.8 + 6.8 71.9 ± 7.3 49.4 + 7.2 
% REM/TST 16.8 _+ 4.5 20.5 + 3.5 27.5 +_ 3.6+ t4.5 ± 2.9 
Wake 2346 _~ 294 2318 * 174 1915 +_ 176" 1800 ± 210"-~: 
non-REM 952 +_ 192 973 ± 127 1211 + 122 1479 _+ 157" 
REM 193 ± 78 315 + 80 484 ± 86 360 + 93 
Mean REM 52.5 + 9.5 76.3 ~ 17.3 52.0 ± 10.4 46.6 ± 4.9 
% REM/TST 12.5 + 3.2 23.7 + 4.~ 27.9 + 3.8* 18.5 _+ 3.8 
* Different from 0 mg/kg, ¢ different from 900 mg/kg, ; different from 100 mg/kg. 
35348 in four different sequences according to a Latin square design 
to control for order effects, so each rat received all three drug doses 
and the control injection. CGP 35348, solved in saline, was admin- 
istered IP at a volume of 2 ml/kg. The drug was kindly donated by 
Ciba Geigy (Basel, Switzerland). The intersession i terval was at 
least 48 h. Pharmacokinetic studies of CGP 35348 have not been 
performed in vivo; pharmacological data show that the EEG effects 
of CGP 35348 disappear in 2 to 3 h after administration [28]. Al- 
though kinetics might be different in old subjects, it is not likely that 
it will largely exceed the half-live values of commonly used rats. 
Therefore, it seems safe to state that the drug effects are not likely 
due to the 48-h wash-out period. Moreover, in a Latin square design, 
order effects are counterbalanced. 
After a recovery period of 10 days, rats were adapted to the 
perspex recording cage (30 × 25 X 35 cm) and to the recording 
leads for 16 h immediately prior injection. Drugs were admin- 
istered at 1000 h. The study was performed in the dark period in 
order to allow putative hypnotic effects to be more easily de- 
monstrable. A ceiling effect in the amount of sleep including 
REM sleep could be present in young adult rats, when measured 
during the light period [33]. EEG and EMG were recorded for 
3 h after injection. The behaviour of the animals was recorded 
through a window from an adjacent room for a period of 30 min, 
from 30 to 60 min after injection. 
Three behavioural categories were distinguished: exploratory be- 
haviour, such as walking, sniffing, and rearing; automatic behaviour, 
such as grooming, eating, and drinking; and immobile behaviour [ 5 ]. 
Sleep and wake states were visually scored according to con- 
ventional EEG and EMG criteria. Wakefulness is characterised 
by a small amplitude, fast frequency EEG together with a high 
amplitude and/or a rapidly changing EMG; non-REM sleep by 
a large amplitude, low frequency EEG together with a moderate 
and relatively constant EMG; whereas REM sleep is character- 
ised by a low voltage, high frequency EEG with predominant 
theta activity, and a low amplitude EMG. Variables, all of which 
were determined for each and for the total of the 3 post-drug 
hours and all of which were scored with an accuracy of I sec, 
were: the duration of wakefulness (W) ,  of non-REM sleep, of 
REM sleep, of total sleep time (TST),  of the percentage REM/ 
TST. the number of sleep periods and the mean duration and, 
finally, the sleep latency (the time elapsing from injection until 
the first period of 30 sec of uninterrupted non-REM) and REM 
sleep latency (time from injection until the first period of 30 sec 
of uninterrupted REM sleep). The LEG analyst was blind to the 
experimental conditions. 
Spike-wave discharges were visually analysed per hour ac- 
cording to criteria reported elsewhere [32]. Briefly, trains of 
spike-waves with a spike (peak) amplitude of at least twice the 
background EEG and a duration of at least 1 sec were assigned 
as spike-wave discharges. 
All sleep parameters and sp ike-wave discharges were ana- 
lysed with an ANOVA with hour (three levels) and dose (four 
levels ) as "within subject" factors. Dose was analysed with sub- 
ject x dose as the error term; hour was tested with hour x subject 
as the error term; and dose x hour was analysed with dose x 
hour x subject as error term. If appropriate, post hoc tests ac- 
cording to Duncan were performed, and here a p-value smaller 
than .05 was considered to reflect significance. Behavioural data, 
overall (3 h) sleep data, non-REM sleep latency, and REM sleep 
latency were statistically evaluated with dose as "within sub- 
ject"  factor and eventually followed by the same post hoc tests. 
RESULTS 
Sleep- Wake Parameters 
The duration of wakefulness, non-REM sleep, REM sleep, 
TST, and percentage REM/TST are presented in Table 1 for each 
hour separately and in Figure 1 for the total 3 h (overall).  With 
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FIG. 1. The effects of various doses (0, 100, 300, and 900 mg/kg) of the GABAB antagonist CGP 35348 on wakefulness, non-REM, REM, Total 
Sleep, percentage REM/TST, and REM sleep latency in the 3-h recording time. Means and SEMs in seconds (except for %REM/TST) are 
depicted. 
respect o wakefulness, ignificant dose (F  = 5.88, df 3,21, p < 
.01 ), hour (F  = 6.68, df 2,14, p < .01 ) and dose x hour inter- 
action (F  = 3.29, df 6,41, p < .05) effects were found. The post 
hoc tests were done separately for each hour since an interaction 
effect was found. These post hoc tests on the data from the first 
hour revealed that, compared to saline, there was less wakeful- 
ness after 300 mg/kg CGP 35348. There was also less wakeful- 
ness in the second hour after 300 and 900 mg/kg. In the third 
hour, the differences between the groups were no longer present. 
In the overall data, waking duration was decreased (F  = 5.84, 
df 3,28, p < .01 ) after 100, 300, and 900 mg/kg CGP 35348, as 
well as the mean duration of the waking periods (F  = 13.48, df 
3,28, p < .0001; the means and SEMs were 310 _+ 28, 185 _+ 
16, 141 _+ 13, and 178 _+ 21 for the saline, 100, 300, and 900 
mg/kg CGP 35348, respectively). The number of waking peri- 
ods was higher (F  = 6.76, df 3,28, p < .001 ) after 100 (35.9 - 
3.0), 300 (39.4 _+ 2.3), and 900 mg/kg (35 _+ 2.4) CGP 35348 
than after saline (24.8 _ 1.8). 
Significant dose (F  = 5.08, df 3,21, p < .01 ), hour (F  = 
6.09, df 2,14, p < .05) and interaction effect between dose 
and hour (F  = 2.81, df 6,41, p < .05) were found for the 
duration of non-REM sleep. The post hoc tests for the first 
hour showed that there was more non-REM sleep after 100 
and 300 mg/kg  CGP 35348 than after saline. In the second 
and third hour, there was more non-REM sleep after 900 mg/  
kg compared to saline and 100 mg/kg  CGP 35348. Overall, 
there was a significant dose effect (F  = 4.57, df 3,28, p < 
.01), and there was more non-REM sleep after 300 and 900 
mg/kg  CGP 35348 than after saline. The number of non-REM 
sleep periods was enhanced after all doses CGP 35348 (F  = 
8.41, df 3,28,p < .001; the means and SEMs were 27.1 _+ 2.6, 
38.1 _+ 2.7, 42.3 -+ 1.7, and 38.0 + 1.7 for the saline, 100, 
300, and 900 mg/kg  groups respectively). The amplitude of 
the slow waves was reduced after the highest dose and, there- 
fore, scoring of non-REM sleep was awkward. An illustration 
of the reduced amplitude of slow wave sleep after 900 mg/kg  
CGP 35348 is presented in Figure 2. 
Significant dose (F  = 4.47, df 3,21, p < .05), hour (F  = 
12.13, df 2,21, p < .001 ), and interaction (F  = 2.78, df 6,41, p 
< .05) effects were present for the duration of REM sleep. The 
post hoc tests showed that there was more REM sleep in the first 
and second hour after 300 mg/kg compared to saline. Other 
groups which showed an increase in REM duration were the 100 
mg/kg in the first hour. The 300 mg/kg group also showed more 
REM sleep in the second hour than the 900 and 100 mg/kg 
groups. In the overall scores, REM sleep duration was affected 
by CGP 35348 (F  = 5.55, df 3,28, p < .01) and this was due to 
an increase after 300 mg/kg compared to saline and 900 mg/kg 
CGP 35348. The number of REM periods was enhanced only in 
the first hour after administration (F  = 8.14, df 3,28, p < .0001 )
due to an increase after 100 and 300 mg/kg CGP 35348; the 
means and SEMs were 1.6 +__ 0.7, 6.5 _ 1.0, 4.1 -4- 0.8, and 1.3 
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FIG. 2. The cortical EEG and the nuchal EMG on which heart activity is ~uperimposed are shown. In the upper two traces, recorded after saline 
injection, a transition from non-REM sleep, via spindles belonging to the intermediate stage [10], to REM sleep and ending with an awakening is 
presented. The beginning and end of the REM sleep period is indicated with arrows. The spindles of intermediate stage are indicated with a star. 
In the lower two traces, a representative example of diminished amplitude of non-REM sleep waves after 900 mg/kg CGP 35348 is given. Here, 
also, a transition from non-REM to REM and wakefulness i presented. Again, the beginning and end of an REM sleep period is indicated with 
arrows. Note the small amplitude during non-REM sleep and the lack of intermediate sleep spindles at the transition from non-REM sleep to REM 
sleep. The sample is taken one and a half hour after drug administration. 
_+ 0.6 for the saline, 100, 300, and 900 mg/kg  CGP 35348 
groups, respect ively) .  
Also, signif icant dose (F  = 5.22, df  3,21, p < .01 ) and hour 
(F  = 22.60, df  2,24, p < .0001 ) effects were found for the per- 
centage REM/TST. It was affected in the first (F  = 7.5, df  3,28. 
p < .001 ) and third (F  = 3.06, df  3,38, p < .05) hour and in 
the overal l  scores (F  = 3.98, df  3,28, p < .05). In the first hour. 
percentage REM/TST  was enhanced after 100 and 300 mg/kg ,  
compared to saline and 900 mg/kg  CGP 35348; in the third hour, 
the 300 mg/kg  group had a higher percentage REM/TST  than 
the saline group. The analyses of  the overall  scores showed a 
h igher  percentage for the 300 mg/kg  group than the saline and 
the 900 mg/kg  group. 
There were no signif icant di f ferences dose effects on non- 
REM sleep latency the means  and SEM's  were 1748 + 348, I 110 
_+ 22 g, 1313 _+ 122 and 1784 _+ 266 for saline, 100, 300, and 
900 mg/kg  CGP35348,  respectively. However,  REM sleep la- 
tency showed a signif icant dose effect (F  = 3.60, df  3,28, p < 
.05). The post hoc test showed that the REM-s leep  latency was 
shorter after 100 and 300 mg/kg  CGP 35348 compared to saline. 
Data are also presented in F igure 1. 
Behaviour 
The befiavioural data are presented in Table 2. A signif icant 
dose effect was found for the duration of  explorat ive behaviour  
(F  = 5.76, df  3,21, p < .01 ). The duration of  explorat ive be- 
haviour was reduced alter 100 and 300 mg/kg  CGP 35348 com- 
pared to saline and 900 mg/kg  CGP 35348. Also, the number  of  
bouts of  explorat ive behaviour  were dependent  on the dose CGP 
35348 (F  = 3.96, df  3,21, p < .05).  After  300 mg/kg ,  there 
were fewer bouts of  explorat ive befiaviour compared to saline. 
As can be inferred from Table 2, CGP 35348 induced sedative 
effects as expressed by an increase of  immobi le  behaviour ;  how- 
TABLE  2 
MEANS AND SEMS OF DURATION IN SECONDS. AND NUMBER OF BOUTS OF EXPLORATIVE, AUTOMATIC. 
AND IMMOBILE BEHAVIOUR RECORDED FROM THE 30TH TILL THE 60TH MINUTE 
AFTER INJECTION OF VARIOUS DOSES OF CGP 35348 
Behaviour 
Automatic Immobile Exploratory 
Dose 
CGP 35348 Duration Bouts Duration Bouts Duration Bouts 
0 293 + 82 14.1 ± 2.9 436 ± 96 10.4+ 1.8 1034 + 162 10.6 + 2.1 
100 86 + 26* 5.8 ± 1.5" 241 ± 103 5.9 + 1.3 1450 + 121 6.6 ± 0.7 
300 60 ± 26*t 5.3 ± 1.3" 161 ± 87 5.6 ± 1.4 1490 ± 108 7.1 ± 0.7 
900 223 ± 46 9.8 + 2.4 3t6 ± 85 6.9 ± 1.8 1220 + 102 8.4 + 1.6 
* Different (p < .05) from 0 mg/kg, 4" different (p < .05) from 900 mg/kg CGP 35348. 
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TABLE 3 
MEANS AND SEMS OF NUMBER AND TOTAL DURATION IN SECONDS OF SPIKE-WAVE DISCHARGES IN FIRST (1), SECOND (2), 
AND THIRD (3) HOUR AP'TER INJECTION OF VARIOUS DOSES OF CGP 35348 
Dose 
CGP 35348 
in mg/kg 
Hour 1 Hour 2 Hour 3 Total 
Number Duration Number Duration Number Duration Number Duration 
0 25.3 _+ 8.0 329 _+ 79 28.0 _ 6.7 408 ± 118 27.5 ± 7.3 330 _+ 78 26.9 _ 4.9 356 ± 52.8 
100 9.5 ± 4.3* 130 ± 98 3.1 ± 2.2* 31 _+ 17' 8.5 ± 2.0* 73 ± 35* 7.0 _+ 2.1"? 86.1 ± 33.3*? 
300 6.0 ± 2.0* 43 ± 22 0.5 ± 0.3* 3 ± 1" 0.0 ± 0.0' 0 ± 0* 2.2 ± 0.9*? 29.8 _ 10.5"? 
900 1.3 ± 1.1" 17 ± 13" 0.0 ± 0.0' 0 ± 0* 0.0 ~ 0.0" 0 --- 0* 0.4 -- 0.4*? 17.0 _+ 3.1*t 
* Different (p < .05) from 0 mg/kg, ?different (p < .05) from all other groups. 
ever, the effects just failed to reach significance (F = 2.86, df 
3,21, p < ,06). 
Spike-Wave Discharges 
A significant dose effect was found (F = 17.56, df 3,21, p < 
.0001 ) for the number of spike-wave discharges. The data are 
presented in Table 3. The reduction in number of spike-wave 
discharges was significant after all three doses of CGP 35348 in 
all 3 h, and all four groups differed from each other according to 
the post hoc tests (p < .05). For the total duration of spike- 
wave discharges also, a significant dose effect was found (F = 
38.20, df 3,14, p < .0001). The post hoc tests confirmed the 
results obtained for the number of spike-wave discharges: all 
three doses significantly reduced the duration of the spike-wave 
discharges in all 3 h. 
DISCUSSION 
The first outcome of the present study was that CGP 35348 
increased REM sleep. This increase in the duration of REM sleep 
could partly be ascribed to an increase in the number of REM 
periods in the first hour after injection and to tendencies in more 
and longer bouts of REM sleep in the other hours. The highest 
dose of CGP 35348 did not further enhance REM sleep compared 
to the middle dose: the increase in REM sleep duration was more 
moderate than what has been found for the middle dose. An in- 
verted u-shaped curve was obtained if REM sleep duration was 
plotted against the dose of CGP 35348. The lack of clear REM 
sleep enhancing effects by the high dose was confirmed by the 
results on the REM sleep latency: this was reduced after 100 and 
300 mg/kg but not after 900 mg/kg of CGP 35348. Upon the 
mechanisms underlying the inverted differences between the 
middle and the highest dose can only be speculated in terms of 
a nonspecific central or peripheral effect or modulation ofanother 
receptor which inhibits REM sleep. REM-enhancing effects are 
rare considering that almost all psychoactive drugs reduce REM 
sleep; until now only a few drugs have been known to promote 
REM sleep: cholinergic agonists uch as carbachol [ 27 ], kainate 
and AMPA agonists [24], and a alpha-2 antagonist [1]. 
Non-REM sleep was enhanced by CGP 35348, and an S- 
shaped dose-response r lationship was suggested by the data. 
Although a frequency spectrum of the EEG was not made, it was 
evident from Figure 2 that the amplitude of the delta waves dur- 
ing non-REM sleep was smaller after CGP 35348, especially 
after the highest dose. This impression is backed up by the work 
of Juh~isz et al., who found that GABAB blockers shifted the 
frequency spectrum belonging to deep slow-wave sleep towards 
that of light slow-wave sleep, while the frequency spectra of 
REM sleep and wakefulness were not altered [13]. The sponta- 
neous behaviour of the rats was altered by the drug at doses 
which reduced wakefulness and induced sleep. 
It is well known that sleep and behavioural patterns in aged 
rats are markedly different from that of juvenile and adult rats, 
and that REM sleep, next to deep slow-wave sleep, is one of the 
parameters most affected by age [25,29]. REM sleep is de- 
creased in old rats [25,29,30]. It cannot be excluded that the 
effects of CGP 35348 can be more easily found in old rats, who 
show a low amount of REM sleep. Perhaps, old rats are a better 
and more suitable model for the study of putative hypnotic drugs 
than young adult rats, which are most often used [33]. 
As previously reported, old Wistar ats show spike-wave dis- 
charges [34,35], and the morphology of the spike-wave dis- 
charges does not appear to be different from the ones we fre- 
quently study in WAG/Rij rats, a genetic model of human 
absence pilepsy [5,6,32]. The spike-wave suppressant effects 
of CGP 35348 are strong and long-lasting, and the effects are 
dose-dependent i  he whole dose range and in all 3 h. The ef- 
ficacy of GABAB antagonists against spike-wave discharges i
unchallenged, as is evident from recent studies in various models 
for generalised absence pilepsy [ 11,16,17,18,28 ]. It is uncertain 
whether and how the hypnotic and the spike-wave discharges' 
suppressant effects relate. It is possible that the hundreds of 
spike-wave discharges per day, covering a considerable time, 
prevent the occurrence ofnormal amounts of non-REM and REM 
sleep. If spike-wave discharges are inhibited by a drug, sleep 
might hen be normalised and an increase in non-REM and REM 
sleep might be the consequence. This is not unlikely since Gan- 
dolfo et al. [10] described more abortive REM sleep periods and 
less REM sleep in spontaneous epileptic than in control rats. 
Therefore, it is interesting tocompare the present results of CGP 
35348 in old rats with data obtained in nonepileptic controls. 
Considering the hypnotic properties of the benzodiazepines, 
which are generally seen as acting as GABA agonists, the evi- 
dence for a role for the neurotransmitter GABA in sleep is not 
unequivocal [19]. Myslobodsky and Mansour [22] found that 
gamma-acetylenic GABA and gamma-vanylic GABA, which 
both inhibit GABA transaminase, do not induce EEG-defined 
sleep. The GABAA agonist muscimol produces an increase in 
waking and a decrease in sleep, especially in REM sleep [4]. 
However, the administration f bicuculline, a GABAA antagonist, 
produced an even greater sleep suppression, which confounds a 
clear interpretation f the role of GABAA in sleep-wake regu- 
lation [4]. In other studies, muscimol did not induce sleep and 
did not potentiate he effects of flurazepam [ 20,21]. It was even 
suggested that the hypnotic effects of the benzodiazepines are 
due to non-GABA-ergic mechanisms [21]. Besides the nega- 
tive or controversial results with respect o the role of GABA 
and sleep, some positive effects have to be mentioned as well. 
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Sallanon et al. [26] injected muscimol in the hypothalamus 
in insomniac ats and found that the GABA agonist restored non- 
REM and REM sleep. Perfusion of GABA in the ventroposter- 
olateral thalamic nuclei produced both an increase in non-REM 
sleep as well in REM sleep [12], whereas an increase in GABA 
could be established during slow-wave sleep [14]. Friess et al. 
[8] described how administration of dehydro-epiandrosterone 
(DHEA) in humans increases rather selectively REM sleep. 
DHEA is regarded as a drug with mixed GABAA agonistic-an- 
tagonistic properties. Lancel and co-workers [15 ] used higher 
doses of muscimol than used by Mendelson and Martin [20] and 
found an increase in both non-REM and REM sleep in rats. Little 
is known about the role of GABAB receptors in sleep, and only 
Juh:4sz et al. [13] described results on non-REM sleep. They 
found a shift in EEG spectra from deep delta to spindling and a 
reduction of deep non-REM sleep and an increase in light non- 
REM sleep in cats. In this experiment, he GABAB antagonists 
saclofen and CGP 35348 were administered in the thalamus 
through dialysis probes. 
In conclusion, this paper reports that the GABA~ antagonist 
CGP 35348 enhances non-REM sleep and REM sleep and re- 
duces strongly spike-wave discharges. Both behavioural and 
EEG parameters contributed to the establishment of a hypnotic 
effect. The highest dose of CGP 35348 was not effective in pro- 
moting REM sleep. The REM-sleep-enhancing effects might 
have theoretical nd clinical relevance. 
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